Langerhans cells are a subset of dendritic cells residing in the epidermis of the human skin. As such, they are key mediators of immune regulation and have emerged as prime targets for novel transcutaneous cancer vaccines. Importantly, the induction of protective T cell immunity by these vaccines requires the efficient and specific delivery of both tumor-associated antigens and adjuvants.
Introduction
The human skin is an attractive vaccination site due to the high density of immune cells compared to other organs such as the muscle 1 . The highly efficacious and cost-effective small pox vaccine was first used via this administration route and has thus proven its feasibility 2 . The skin contains several subsets of dendritic cells (DCs), immune cells that are specialized in the internalization of pathogens and the presentation of antigens to induce T cell responses 3 . Langerhans cells (LCs) constitute a subset of DCs residing in the epidermis of the stratified as well as the mucosal skin. Following their activation, LCs migrate to the draining lymph nodes to elicit systemic immune responses 4 . Due to their localization in the epidermis and their ability to cross-present exogenous antigens to cytotoxic T cells, LCs have emerged as promising targets for transcutaneous vaccination strategies [5] [6] [7] . Various approaches avoiding hypodermic injections have been explored to improve patient care and vaccination costs 1 . For example, microneedles and thermal ablation overcome the stratum corneum and thereby facilitate antigen delivery to the skin.
Sipuleucel-T, an adoptive cell therapy for prostate cancer, has provided proof of concept for the induction of protective cytotoxic T cell responses against tumor-associated antigens (TAAs) by myeloid immune cells 8 . Moreover, the adoptive transfer of monocyte-derived DCs into melanoma patients has been demonstrated to elicit TAA-specific T cell immunity 9 . As ex vivo strategies remain laborious and expensive, the focus has shifted towards the delivery of antigens in situ 10 . Intriguingly, DCs express several endocytic receptors including chemokine receptors, scavenger receptors and C-type lectin receptors (CLRs) that promote the internalization and cross-presentation of antigens [11] [12] [13] . Pioneered by Steinman et al., the use of antibody-antigen conjugates targeting CLRs such as DEC-205, DC-SIGN and DNGR-1 represents an established strategy to deliver antigens to DCs and has translated into clinical trials [14] [15] [16] [17] . These investigations helped identify several parameters that shape cytotoxic T cell immunity and guide the development of next-generation cancer vaccines. First, the activation of DCs by coadministration of adjuvants such as Toll-like receptor (TLR) or Rig-I-like receptor agonists is required to avoid tolerance induction 18 . Furthermore, the choice of delivery platform and targeting ligand influence the efficiency of antigen internalization, processing and cross-presentation by DCs [19] [20] [21] [22] .
Finally, the specific targeting of individual DC subsets is essential as of off-target delivery of antigens and adjuvants may result in adverse effects or compromised cytotoxic T cell immunity 23, 24 .
Consequently, DC subset-specific receptors such as the CLRs Langerin and DNGR-1 as well as the chemokine receptor XCR1 have become a focal point for the development of novel immunotherapies 13, 17 .
Langerin (CD207), an endocytic CLR exclusively expressed on human LCs, has been shown to promote the cross-presentation of antigens to prime cytotoxic T cells 4, 25 . The trimeric CLR thus represents an attractive target receptor for transcutaneous vaccination strategies 26 . In this study, we pursued the development of targeted nanoparticles as an antigen delivery platform for LCs to address the limitations of antibody-based approaches. Liposomes represent versatile nanoparticles that have been approved for the delivery of chemotherapeutics in Kaposi's sarcoma and allow for the co-formulation of adjuvants 27, 28 . They can be targeted to glycan-binding proteins (GBPs) including CLRs or sialic acidbinding immunoglobulin-like lectins (Siglecs) expressed on immune cells using glycans or glycomimetic ligands [29] [30] [31] .
Glycan recognition by Langerin is Ca 2+ -as well as pH-dependent and consequently abrogated in the early endosome, thereby limiting lysosomal antigen degradation 32 . This release mechanism simultaneously increases the internalization capacity of LCs as unbound Langerin has been shown to recycle to the plasma membrane 33 . Hence, the use of glycans or glycomimetics provides advantages over antibody-based approaches which potentially suffer from inefficient ligand release 20, 21 .
Furthermore, antibodies are prone to denaturation and their large-scale production is expensive. Despite recent advances in antibody engineering such as humanization and defined glycosylation profiles, antibody-based therapies remain limited by Fc receptor-mediated immunogenicity and clearance 34 .
As glycans are typically recognized by several CLRs or other GBPs, they do not provide the specificity required to target individual DC subsets 35 . Additionally, glycan-Langerin interactions display low affinities insufficient to promote the endocytosis of liposomes [36] [37] [38] [39] . This renders the design of potent and specific glycomimetic ligands essential for the development of an antigen delivery platform for LCs.
The carbohydrate binding sites of CLRs are hydrophilic and solvent-exposed which has impeded the discovery of drug-like molecule ligands 40, 41 . While mono-and oligosaccharides represent attractive scaffolds, the synthesis of carbohydrates and structural glycomimetics is generally considered onerous 42, 43 . Nevertheless, individual reports have demonstrated the feasibility of ligand design for these challenging target receptors and other GBPs [44] [45] [46] [47] . Many of these reports highlight the utility of concepts from rational and fragment-based drug discovery for glycomimetic ligand design.
Here, we present the discovery of the first micromolar glycomimetic ligand for Langerin. Combining NMR spectroscopy and molecular docking, we rationally designed heparin-derived monosaccharide analogs. The targeting ligand facilitated the endocytosis of liposomes by LCs and provides remarkable specificity over other GBPs in a physiologically relevant ex vivo skin model. Hence, our findings demonstrate the CLR-mediated targeting of nanoparticles to individual immune cell subsets using glycomimetics.
Results

Heparin-derived monosaccharides represent favorable scaffolds for glycomimetic ligand design
Aside from its function as a pathogen recognition receptor, Langerin interacts with self-antigens such as glycosaminoglycans including heparin 39, 48, 49 . These linear polysaccharides are composed of disaccharide repeating units consisting of galactose or uronic acids and differentially sulfated N-acetyl glucosamine (GlcNAc). Prompted by the 10-fold affinity increase (KD = 0.49±0.05 mM) over mannose (Man) disaccharides (KD = ca. 4 mM) recently reported for a heparin-derived trisaccharide, we employed ligand-observed 19 F R2-filtered NMR experiments to determine KI values for a set of differentially sulfated GlcNAc derivatives ( Figure 1a ) 37, 39, 50 . Interestingly, the affinities of glucosamine-2-sulfate (GlcNS) (KI = 1.4±0.2 mM), N-acetyl glucosamine-6-sulfate (GlcNAc-6-OS) (KI = 0.6±0.1 mM) and glucosamine-2-sulfate-6-sulfate (GlcNS-6-OS) (KI = 0.28±0.06 mM) were comparable or higher than those observed for heparin-derived oligosaccharides and other monosaccharides including Glc (KI = 21±4 mM), GlcNAc (KI = 4.1±0.7 mM) and Man (KI = 4.5±0.5 mM) ( Supplementary Figure 1 , Supplementary Table 1) 48 .
GlcNS-6-OS, representing the most potent monosaccharide identified, displayed an additive structureactivity relationship (SAR) for the sulfation in C2 and C6. This affinity increase is based on the formation of salt bridges with K299 and K313 as previously shown by X-ray crystallography 51 . GlcNS-6-OS displayed an altered orientation of the Glc scaffold compared to the Langerin-GlcNAc complex (Figure 1b) 38 . The affinity increase observed over Glc observed for GlcNAc, on the other hand, is the result of an H2O-mediated hydrogen bond with K299. Importantly, either of these interactions might be leveraged for glycomimetic ligand design via the bioisosteric substitution of the sulfate groups with a sulfonamide linker. In particular, the synthesis of GlcNS analogs represents a feasible fragment growing approach to explore the carbohydrate binding site for favorable interactions (Figure 1a ). These characteristics render sulfated GlcNAc derivatives favorable scaffolds for the design of glycomimetic Langerin ligands.
Small aromatic sulfonamide substituents render glycomimetics potent targeting ligands for Langerin and provide specificity against DC-SIGN
Assuming the conservation of the Glc scaffold orientation observed for GlcNAc, small aromatic substituents in C2 were hypothesized to increase the affinity by the formation of cation-π interactions with K299 and K313 or π-π and H-π interactions with F315 and P310, respectively ( Figure 1b ). Accordingly, a panel of GlcNS analogs 1 to 5 bearing differentially substituted phenyl rings was prepared and followed by the determination of KI values (Figure 1a , Supplementary Scheme 1, Supplementary Figure 2 ). Increased affinities over GlcNAc were observed for all analogs, with a 13-fold affinity increase for 2 (KI = 0.32±0.05 mM), the most potent panel member (Table 1 , Supplementary   Figure 3 , Supplementary Table 2 ). The analog bears a methyl group in para position of the phenyl ring that does not contribute substantially to the affinity increase, as exemplified by the KI value obtained for 1 (KI = 0.37±0.04 mM).
Despite its low complexity, 2 displays an affinity superior to that of glycans previously applied as targeting ligands for DC subsets distinct from LCs 29 . Here, the blood group antigen Le X (KD,DC-SIGN = ca. 1 mM) was demonstrated to promote the DC-SIGN-dependent internalization of liposomes by isolated dermal DCs to activate T cells in vitro 52 . Encouraged by these reports, we advanced 2 towards targeted delivery applications via the introduction of an ethylamino linker in β-orientation of C1 of the Glc scaffold to yield targeting ligand 15 (Figure 1a Table 1 , Supplementary Figure 5 ). Likewise, the affinity of 2 was validated using 15 N HSQC NMR (KD,fast = 0.46±0.04 mM, KD,slow = 0.5±0.2 mM) ( Table 1 , Supplementary Figure 6 ).
Next, we explored the specificity of targeting ligand 16 against DC-SIGN as such off-target affinity would imply a reduced efficiency of the approach and the potential induction of adverse effects. For this purpose, we transferred the 19 F R2-filtered NMR reporter displacement assay to DC-SIGN ( Supplementary Figure 7 , Supplementary Table 3 ). Strikingly and Man (KI,DC-SIGN = 3.0±0.3 mM) revealed that the differential recognition of α-and β-glycosides by these CLRs contributes to specificity ( Table 1 , Supplementary Figure 8 ).
The formation of π-π interactions and hydrogen bonds by aromatic sulfonamide substituents mediate an affinity increase for Langerin
To investigate the binding mode of model ligand 16, 15 Finally, molecular docking was performed utilizing the X-ray structure of the Langerin complex with GlcNAc (Figure 2e , Supplementary Figure 13 ) 38 . Generated docking poses were evaluated in the context of the NMR experiments and representative poses were selected to visualize the formation of potential secondary interactions. Indeed, orienting the phenyl ring towards F315 resulted in the formation of π-π interactions. This orientation also coincided with the formation of a weak hydrogen bond between the sulfonamide linker and N307. Both interactions explain the pronounced CSP values observed for residues that are associated with F315 and N307 including I250, Y251, N297 and K299. Furthermore, the phenyl ring received high STD effects indicating the formation of secondary interaction and high proximity to the Langerin surface. Conversely, the acetylated ethylamino linker displayed high solvent exposure and no conserved secondary interactions for the majority of docking poses. This observation was in accordance with the low STD effects and thus validated the developed conjugation strategy for GlcNS analogs. Overall, we propose a binding mode for 16 that displays a conserved orientation of the Glc scaffold, consistent with both STD and 15 N HSQC NMR experiments. The affinity increase can be rationalized by the formation of π-π interactions between the phenyl substituent and F315 as well as a hydrogen bond between the sulfonamide linker and N297.
Targeted liposomes specifically bind to Langerin + cells in vitro
Next, monosaccharide analogs 15 or 20 were utilized to synthesize glycolipids 22 and 23, respectively 
Langerhans cells of the human epidermis efficiently internalize targeted liposomes
To explore the binding and subsequent internalization of the delivery platform by primary cells, we prepared epidermal cell suspensions from skin biopsies (Figure 4a ) 53 . The cells were incubated with targeted and non-targeted liposomes for 1 h at 37°C and analyzed by flow cytometry. Upon incubation with liposomes 22, more than 95% of gated HLA-DR + -CD45 + -CD1a high LCs were found to display AF 647 + fluorescence ( Figure 4b ). As for the Raji cells, binding was dependent on the targeting ligand and could be abrogated by simultaneous incubation with EDTA. The interaction was highly specific in the context of the human epidermis as neither keratinocytes, melanocytes nor T cells were targeted ( Figure   4c ).
Next, the kinetics of endocytosis by LCs were evaluated by adding EDTA at different times after the incubation with the delivery platform ( Figure 4d ). From these experiments, it can be inferred that more than 95% of gated LCs had internalized targeted liposomes after 20 min. The continuous increase in AF 647 + fluorescence was monitored for up to 60 min, further 
22.Targeted liposomes exclusively address Langerin + cells of the human skin
As an alternative to epicutaneous administration, intradermal injection represents an attractive vaccination strategy for the skin 26, 54 . However, the human dermis contains additional antigen-presenting cells including dermal DCs, macrophages and monocytes. These cells express a variety of GBPs such as MR, Dectin-1, DC-SIGN and Siglec-10 and hence represent potential targets for glycomimetics 55 . In analogy to the experiments with epidermal skin cell suspensions, whole skin cell suspensions were utilized to analyze the specificity of the delivery platform in a physiologically relevant context ( Figure   5 
Discussion
Human LCs have been recognized for their capacity to internalize and cross-present exogenous antigens to elicit cytotoxic T cell responses, an established strategy for the development of novel cancer immunotherapies 5, 6 . They reside in the epidermis of the skin and have consequently emerged as prime targets for transcutaneous vaccines 7, 26 . However, the induction of protective T cell immunity remains challenging, requiring the efficient and specific delivery of antigens as well as adjuvants. In the absence of adjuvants, LCs induce tolerance while the off-target delivery of antigens or adjuvants potentially results in adverse effects and compromises the quality of the cytotoxic T cell response 23, 24 . In this study, we present the development of a liposomal delivery platform that specifically addresses LCs in the context of the human skin to overcome these challenges.
Beyond their relevance for transcutaneous vaccination strategies, our findings provide the proof-ofconcept for CLR-mediated targeting of nanoparticles to individual immune cell subsets using glycomimetics. The discovery of ligand 15 (KI = 0.24±0.03 mM) with micromolar affinity for Langerin represents the essential innovation required to achieve efficient internalization of liposomes by LCs.
Previous ex vivo studies have explored the use of natural glycans such as Le Y for this purpose 29 .
Interestingly, Le Y did not promote endocytosis by LCs while the Le X -mediated (KD,DC-SIGN = ca. 1 mM) targeting of DC-SIGN on dermal DCs succeeded 52 . At the time, the authors concluded that liposomal formulations are not suitable to address LCs. Here, we propose the concept of CLR-specific avidity thresholds to explain these findings. The affinities of the utilized natural glycans for Langerin and DC-SIGN were comparable. Yet, the targeted liposomes presumably displayed an increased avidity for dermal DCs due the tetrameric organization of the carbohydrate recognition domains, the formation of nanoclusters or increased expression levels for DC-SIGN 56 .
These characteristics renders LCs more difficult targets for glycan-mediated liposomal delivery compared to dermal DCs. Here, we have demonstrated that this difficulty can be overcome by glycomimetic ligand design. While generally considered challenging in itself, the design of mono-or oligosaccharide analogs has been successfully applied to target delivery platforms to other GBPs such as ASGPR and Siglec-2 57, 58 . The 42-fold affinity increase over natural glycans observed for 15, by proxy of model ligand 16, exceeds that reported for other first-generation glycomimetics and highlights the success of our heparin-inspired rational design strategy [58] [59] [60] . Notably, 15 provides improved synthetic feasibility and metabolic stability over sulfated heparin-derived mono-(KI = 0.28±0.06 mM) or trisaccharides (KD = 0.49±0.05 mM) which display similar affinities 39 . The SAR obtained for the Glc scaffold suggests that the formation β-glucosides represents the superior conjugation strategy compared to the use of α-mannosides previously explored 50 .
Using NMR spectroscopy and molecular docking, we have proposed a Ca 2+ -dependent binding mode for 15 which likely resembles that of GlcNAc 38 . The conserved orientation of the Glc scaffold allows for the formation of π-π interactions between the phenyl ring and F315 as well as a hydrogen bond between the sulfonamide linker and N307. We conclude that these interactions contribute substantially to the affinity increase observed for 15. The combination of the obtained SAR with our binding mode analysis will inform the design of next-generation glycomimetics. Attractive approaches to further optimize the affinity for Langerin include the introduction of sulfonamide substituents in C6 to mimic the interactions formed by GlcNS-6-OS and the introduction of electron-donating substituents on the phenyl ring 61 . Notably, our analysis does not account for conformational flexibility of the carbohydrate binding site and our analysis is furthermore limited by an incomplete resonance assignment for Langerin. Hence, X-ray crystallography will serve to validate the proposed binding mode for 15 moving forward.
In summary, liposomes bearing targeting ligand 15 were efficiently internalized both by model cells 63 . Intriguingly, this observation might be leveraged to infer general design principles for specific nanoparticle-based delivery platforms. Overall, our findings highlight not only the therapeutic potential of the targeted liposomes but also their value as molecular probes for basic research where they will potentially contribute to studying the role of LCs in skin homeostasis or to elucidate the mechanisms of antigen cross-presentation 64 .
In contrast to other CLRs, Langerin-dependent signaling has not been reported to date 65 . Our findings support this hypothesis as the binding and endocytosis of targeted liposomes did not activate immature LCs ex vivo. This expands the therapeutic scope of the liposomal delivery platform. On the one hand, the co-administration of adjuvants, preferably TLR-3 or MDA5 agonists, will promote the induction of cytotoxic T cell immunity required for cancer vaccines 25, 66, 67 . As both are intracellular pattern recognition receptors, facilitating the internalization of these agonists is of particular importance. On the other hand, antigen delivery to LCs in absence of adjuvants has been shown to result in the expansion of regulatory T cells and can be leveraged to treat autoimmune diseases 68 . In this context, liposomes are superior to antibody-antigen conjugates as they enable the co-formulation of antigens and adjuvants.
While the systemic administration of adjuvants generally induces adverse effects and compromises cytotoxic T cell immunity, their targeted delivery to LCs allows for reduced adjuvant doses and tailored immune responses.
Moreover, many CLRs including Langerin recycle between the plasma membrane and the endosomal compartment 33 . In this context, the Ca 2+ -and pH-dependent release of glycomimetic ligands in the early endosome increases the endocytic capacity of LCs and other DCs 48 . It can be argued that this intracellular trafficking mechanism evolved to promote antigen cross-presentation 69 . The observed fast internalization kinetics and the prolonged co-localization of targeted liposomes with early endosomal markers suggest that this mechanism is efficiently exploited. By contrast, antibodies have been demonstrated to recycle back to the plasma membrane, thereby limiting the dose of internalized and processed antigens 20, 21 . These characteristics highlight another potential advantage of the liposomal delivery platform over antibody-based approaches.
Future investigations will advance the developed liposomal delivery platform for LCs towards in vivo studies. Here, it will be essential to demonstrate the LC-mediated induction of cytotoxic T cell responses.
Important parameters of this process that remain to be investigated are the intracellular trafficking and the efficient cross-presentation of delivered antigen. Finally, the feasibility of transcutaneous vaccinations using targeted liposomes will be evaluated to pave the way for therapeutic applications.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Synthetic Chemistry
Synthetic procedures and characterization for monosaccharide analogs and glycolipids are provided as 74 . Spectra were processed in NMRPipe 75 . Data analysis was performed using CCPN Analysis, MatLab and OriginPro 71, 76, 77 . Experiments with the Langerin CRD were performed at a receptor concentration of 100 µM in 25 mM HEPES with 10% D2O, 150 mM NaCl and 5 mM CaCl2 at pH 7.8 and 25° C. DSS-d6 served as an internal reference at a concentration of 100 µM. Spectra were referenced via the internal spectrometer reference. Spectra were acquired with 128 increments and 32 scans per increments for 150 µl samples in 3 mm sample tubes. The relaxation delay d1 was set to 1.4 s and the acquisition time tacq was set to 100 ms. The W5 Watergate pulse sequence was used for solvent suppression 78 . The used resonance assignment for the Langerin CRD has been published previously 32 . A standard deviation σ of 0.02 ppm was previously determined for the measurement of chemical shifts in 15 The apparent saturation rate ksat and the maximal STD effect STDmax were derived from Equation 5 in a two parameter fit 86 . Standard errors were derived directly from the fitting procedures. These parameters were used to calculate the initial slope of the STD build-up curves STD'0 via Equation 6 . STD'0 values were normalized and mapped on the corresponding ligand structure. Only resonances for which at least part of a multiplet was isolated were considered for the epitope mapping. 
Liposomal Formulation
PEGylated liposomes were prepared via thin film hydration and subsequent pore extrusion as previously published 92 To monitor internalization and binding, liposomes and, in case of control experiments, 10 mM EDTA or 50 µg·ml -1 mannan in PBS were added to 96 well microtiter plates (Nunc). Cells were counted, centrifuged at 500 g for 3 min, aspirated and resuspended in culture medium at 37° C and 5% CO2. 15 Figure 6 ). Overall, the majority of residues displaying increased CSPs can be associated with N307 and F315, which could not be assigned 32 d. STD NMR experiments served to further validate the interaction formed between 16 and Langerin. STD NMR spectra were recorded at saturation times tsat of 0.4 s and are magnified 8-fold. Epitopes determined from build-up curves suggest strong interactions formed by the phenyl substituent ( Supplementary Figure 10) . By contrast, low relative STD'0 values were observed for the acetylated ethylamino linker, consistent with a solvent exposed orientation. e. 16 was docked into the carbohydrate binding site to rationalize the observations from 15 N HSQC and STD NMR experiments. The selected docking pose predicted the formation of π-π interactions between the phenyl ring and F315 as well as the formation of a hydrogen bond between the sulfonamide group and N307. The linker displays high solvent exposure. The receptor surface is colored according to its lipophilicity (lipophilic: red, hydrophilic: blue). 
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